{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:41:52Z","timestamp":1789540912340,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71904155"],"award-info":[{"award-number":["71904155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the key research and development program in Shaanxi province of China","award":["2019ZDLSF01-05"],"award-info":[{"award-number":["2019ZDLSF01-05"]}]},{"name":"the Key Research and Development Program of Shaanxi","award":["2020SF-064"],"award-info":[{"award-number":["2020SF-064"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["xzy012019079"],"award-info":[{"award-number":["xzy012019079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bacterial infections are common complications in patients with cirrhosis or liver failure and are correlated with high mortality. Clinical practice guideline (CPG) is a reference used to help clinicians make decisions. This systematic appraisal aimed to evaluate the methodological quality and summarize the recommendations of reported CPGs in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched CPGs published from 2008 to 2019. The methodological quality of the included CPGs was assessed using the AGREE II instrument. We extracted and compared recommendations for prophylactic and empirical treatment strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen CPGs with a median overall score of 56.3% were included. The highest domain score was Clarity of Presentation (domain 4, 85.4%), and the lowest was for Stakeholder Involvement (domain 2, 31.3%). Three CPGs had an overall score above 80%, and 6 CPGs had a score above 90% in domain 4. Prophylaxis should be strictly limited to patients with varicose bleeding, low ascites protein levels and a history of spontaneous bacterial peritonitis. Fluoroquinolones (norfloxacin and ciprofloxacin), third-generation cephalosporins (G3) (ceftriaxone and cefotaxime) and trimethoprim\u2013sulfamethoxazole (SXT) are recommended for preventing infections in patients with cirrhosis or liver failure. G3, \u03b2-lactam\/\u03b2-lactamase inhibitor combinations (BLBLIs) and carbapenems are recommended as the first choice in empirical treatment according to local epidemiology of bacterial resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The methodological quality of CPGs focused on patients with cirrhosis or liver failure evaluated by the AGREE II instrument is generally poor. Three CPGs that were considered applicable without modification and 6 CPGs that scored above 90% in domain 4 should also be paid more attention to by healthcare practitioners. Regarding recommendations, norfloxacin, ciprofloxacin, ceftriaxone, cefotaxime, and SXT are recommended for prophylactic treatment appropriately. G3, BLBLIs, and carbapenems are recommended for use in empirical treatment strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-07018-2","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:05:09Z","timestamp":1641294309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure"],"prefix":"10.1186","volume":"22","author":[{"given":"Yuzhu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gezhi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"7018_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60002-6","volume":"56","author":"J Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56:S1\u201312.","journal-title":"J Hepatol"},{"key":"7018_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/hep.27077","volume":"1","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS, O\u2019Leary JG, Reddy KR, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;1:250\u20136.","journal-title":"Hepatology"},{"key":"7018_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/jhep.2002.30082","volume":"1","author":"J Fern\u00e1ndez","year":"2002","unstructured":"Fern\u00e1ndez J, Navasa M, G\u00f3mez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;1:140\u20138.","journal-title":"Hepatology"},{"key":"7018_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajem.2014.11.024","volume":"2","author":"C-C Hsieh","year":"2015","unstructured":"Hsieh C-C, Lee C-C, Chan T-Y, Hong M-Y, Chi C-H, Ko W-C. Clinical features and impact of empirical therapy in cirrhotic adults with community-onset bacteremia. Am J Emerg Med. 2015;2:222\u20138.","journal-title":"Am J Emerg Med"},{"key":"7018_CR5","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3748\/wjg.v21.i12.3587","volume":"12","author":"H Park","year":"2015","unstructured":"Park H, Jang KJ, Jang W, et al. Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia. World J Gastroenterol. 2015;12:3587\u201392.","journal-title":"World J Gastroenterol"},{"key":"7018_CR6","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/cid\/ciz540","volume":"9","author":"MM M\u00fccke","year":"2020","unstructured":"M\u00fccke MM, Mayer A, Kessel J, et al. Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2020;9:1916\u201324.","journal-title":"Clin Infect Dis"},{"key":"7018_CR7","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1053\/j.gastro.2018.12.005","volume":"5","author":"S Piano","year":"2019","unstructured":"Piano S, Singh V, Caraceni P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology. 2019;5:1368-1380.e10.","journal-title":"Gastroenterology"},{"key":"7018_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/MCG.0000000000000820","volume":"2","author":"EB Tapper","year":"2018","unstructured":"Tapper EB, Friderici J, Borman ZA, et al. A multicenter evaluation of adherence to 4 major elements of the baveno guidelines and outcomes for patients with acute variceal hemorrhage. J Clin Gastroenterol. 2018;2:172\u20137.","journal-title":"J Clin Gastroenterol"},{"key":"7018_CR9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","volume":"4","author":"DV Cicchetti","year":"1994","unstructured":"Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;4:284\u201390.","journal-title":"Psychol Assess"},{"key":"7018_CR10","first-page":"406","volume":"2","author":"European Association for The Study of the Liver","year":"2018","unstructured":"European Association for The Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;2:406\u201360.","journal-title":"J Hepatol"},{"key":"7018_CR11","first-page":"164","volume":"2","author":"Liver Failure and Artificial Liver Group","year":"2019","unstructured":"Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Diseases and Artificial Liver Group Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure (2018). J Clin Hepatol. 2019;2:164\u201371.","journal-title":"J Clin Hepatol"},{"key":"7018_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","volume":"5","author":"J Wendon","year":"2017","unstructured":"Wendon J, Cordoba J, Dhawan A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;5:1047\u201381.","journal-title":"J Hepatol"},{"key":"7018_CR13","first-page":"230","volume":"3","author":"KASL clinical practice guidelines for liver cirrhosis","year":"2018","unstructured":"KASL clinical practice guidelines for liver cirrhosis. Ascites and related complications. Clin Mol Hepatol. 2018;3:230\u201377.","journal-title":"Clin Mol Hepatol"},{"key":"7018_CR14","first-page":"1","volume":"1","author":"X Xu","year":"2018","unstructured":"Xu X, Ding H, Li W, et al. Diagnostic and treatment guidelines for cirrhotic ascites and related complications (2017 Beijing). Chin J Gastrointest Endosc. 2018;1:1\u201317 (Electronic Edition).","journal-title":"Chin J Gastrointest Endosc"},{"key":"7018_CR15","volume-title":"Cirrhosis in over 16s: assessment and management","author":"GC National","year":"2016","unstructured":"National GC. Cirrhosis in over 16s: assessment and management. London: National Institute for Health and Care Excellence; 2016."},{"key":"7018_CR16","first-page":"203","volume":"2","author":"X Xu","year":"2016","unstructured":"Xu X, Ding H, Jia J, et al. Guidelines for the prevention and treatment for portal hypertension related esophagogastric variceal bleeding. J Clin Hepatol. 2016;2:203\u201319.","journal-title":"J Clin Hepatol"},{"key":"7018_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","volume":"7","author":"H Fukui","year":"2016","unstructured":"Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;7:629\u201350.","journal-title":"J Gastroenterol"},{"key":"7018_CR18","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/gutjnl-2015-309262","volume":"11","author":"D Tripathi","year":"2015","unstructured":"Tripathi D, Stanley AJ, Hayes PC, et al. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;11:1680\u2013704.","journal-title":"Gut"},{"key":"7018_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12072-014-9580-2","volume":"4","author":"SK Sarin","year":"2014","unstructured":"Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) 2014. Hepatol Int. 2014;4:453\u201371.","journal-title":"Hepatol Int"},{"key":"7018_CR20","first-page":"346","volume":"4","author":"LJ Li","year":"2013","unstructured":"Li LJ. 13th asia-pacific congress of clinical microbiology and infection consensus guidelines for diagnosis and treatment of liver failure. Hepatobiliary Pancreat Dis Int. 2013;4:346\u201354.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"7018_CR21","unstructured":"The American Association for the Study of Liver Diseases. Management of adult patients with ascites due to cirrhosis: update 2012."},{"key":"7018_CR22","first-page":"397","volume":"3","author":"European Association for the Study of the L","year":"2010","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;3:397\u2013417.","journal-title":"J Hepatol"},{"key":"7018_CR23","unstructured":"Scottish Intercollegiate Guidelines Network. Management of acute upper and lower gastrointestinal bleeding: a national clinical guideline. September 2008."},{"issue":"6","key":"7018_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF00637745","volume":"36","author":"L Hary","year":"1989","unstructured":"Hary L, Andrejak M, Leleu S, et al. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites. Eur J Clin Pharmacol. 1989;36(6):613\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"44","key":"7018_CR25","first-page":"2331","volume":"17","author":"P Vincent","year":"1988","unstructured":"Vincent P, Colombel JF, Husson MO, et al. Pharmacokinetics of cefotaxime in cirrhotic patients with or without ascites. Presse Med. 1988;17(44):2331\u20134.","journal-title":"Presse Med"},{"key":"7018_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.mayocp.2018.12.036","volume":"8","author":"DB Sunjaya","year":"2019","unstructured":"Sunjaya DB, Lennon RJ, Shah VH, Kamath PS, Simonetto DA. Prevalence and predictors of third-generation cephalosporin resistance in the empirical treatment of spontaneous bacterial peritonitis. Mayo Clin Proc. 2019;8:1499\u2013508.","journal-title":"Mayo Clin Proc"},{"key":"7018_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/hep.27941","volume":"4","author":"S Piano","year":"2016","unstructured":"Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial. Hepatology. 2016;4:1299\u2013309.","journal-title":"Hepatology"},{"key":"7018_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijid.2019.10.016","volume":"89","author":"Y Wang","year":"2019","unstructured":"Wang Y, McGuire TM, Hollingworth SA, et al. Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: what do the guidelines recommend? Int J Infect Dis. 2019;89:137\u201345.","journal-title":"Int J Infect Dis"},{"key":"7018_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/bjsports-2017-098375","volume":"5","author":"I Lin","year":"2018","unstructured":"Lin I, Wiles LK, Waller R, et al. Poor overall quality of clinical practice guidelines for musculoskeletal pain: a systematic review. Br J Sports Med. 2018;5:337\u201343.","journal-title":"Br J Sports Med"},{"key":"7018_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jhep.2017.06.028","volume":"5","author":"P Gavriilidis","year":"2017","unstructured":"Gavriilidis P, Roberts KJ, Askari A, et al. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the appraisal of guidelines for research and evaluation II instrument. J Hepatol. 2017;5:991\u20138.","journal-title":"J Hepatol"},{"key":"7018_CR31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41395-018-0168-7","volume":"8","author":"HJ Yim","year":"2018","unstructured":"Yim HJ, Suh SJ, Jung YK, et al. Daily norfloxacin vs. weekly ciprofloxacin to prevent spontaneous bacterial peritonitis: a randomized controlled trial. Am J Gastroenterol. 2018;8:1167\u201376.","journal-title":"Am J Gastroenterol"},{"key":"7018_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1053\/j.gastro.2018.08.026","volume":"6","author":"R Moreau","year":"2018","unstructured":"Moreau R, Elkrief L, Bureau C, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;6:1816-27.e9.","journal-title":"Gastroenterology"},{"key":"7018_CR33","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/liv.14109","volume":"8","author":"A Facciorusso","year":"2019","unstructured":"Facciorusso A, Papagiouvanni I, Cela M, Buccino VR, Sacco R. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int. 2019;8:1448\u201358.","journal-title":"Liver Int"},{"key":"7018_CR34","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jhep.2018.12.032","volume":"5","author":"A Lombardi","year":"2019","unstructured":"Lombardi A, Zuccaro V, Fagiuoli S, Bruno R. Prophylaxis of spontaneous bacterial peritonitis: is there still room for quinolones? J Hepatol. 2019;5:1027\u20138.","journal-title":"J Hepatol"},{"key":"7018_CR35","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/apt.14361","volume":"11\u201312","author":"A Goel","year":"2017","unstructured":"Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017;11\u201312:1029\u201336.","journal-title":"Aliment Pharmacol Ther"},{"key":"7018_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","volume":"2","author":"M Assem","year":"2016","unstructured":"Assem M, Elsabaawy M, Abdelrashed M, et al. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. Hepatol Int. 2016;2:377\u201385.","journal-title":"Hepatol Int"},{"key":"7018_CR37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/apt.14544","volume":"7","author":"T Th\u00e9venot","year":"2018","unstructured":"Th\u00e9venot T. Letter: using a placebo as a comparator to rifaximin for the primary prophylaxis of spontaneous bacterial peritonitis\u2014is there really an ethical concern? Aliment Pharmacol Ther. 2018;7:1047\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"7018_CR38","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/hep.25532","volume":"55","author":"J Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551\u201361.","journal-title":"Hepatology"},{"key":"7018_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127448","volume":"10","author":"M Merli","year":"2015","unstructured":"Merli M, Lucidi C, Di Gregorio V, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS ONE. 2015;10: e0127448.","journal-title":"PLoS ONE"},{"key":"7018_CR40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cgh.2012.08.017","volume":"10","author":"P Tandon","year":"2012","unstructured":"Tandon P, DeLisle A, Topal JE, et al. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol. 2012;10:1291\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7018_CR41","volume":"9","author":"L Iogna Prat","year":"2019","unstructured":"Iogna Prat L, Wilson P, Freeman SC, et al. Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019;9: CD013120.","journal-title":"Cochrane Database Syst Rev"},{"key":"7018_CR42","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.3748\/wjg.v23.i25.4654","volume":"25","author":"M Fiore","year":"2017","unstructured":"Fiore M, Maraolo AE, Gentile I, et al. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: a systematic review. World J Gastroenterol. 2017;25:4654\u201360.","journal-title":"World J Gastroenterol"},{"key":"7018_CR43","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1086\/597585","volume":"9","author":"HS Cheong","year":"2009","unstructured":"Cheong HS, Kang C-I, Lee JA, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis. 2009;9:1230\u20136.","journal-title":"Clin Infect Dis"},{"key":"7018_CR44","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.dld.2019.02.015","volume":"9","author":"A Wieser","year":"2019","unstructured":"Wieser A, Li H, Zhang J, et al. Evaluating the best empirical antibiotic therapy in patients with acute-on-chronic liver failure and spontaneous bacterial peritonitis. Dig Liver Dis. 2019;9:1300\u20137.","journal-title":"Dig Liver Dis"},{"key":"7018_CR45","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1086\/317494","volume":"31","author":"AM Thulstrup","year":"2000","unstructured":"Thulstrup AM, S\u00f8rensen HT, Sch\u00f8nheyder HC, et al. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis. 2000;31:1357\u201361.","journal-title":"Clin Infect Dis"},{"issue":"69","key":"7018_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-med-052716-030320","volume":"29","author":"EL Tsalik","year":"2018","unstructured":"Tsalik EL, Bonomo RA, Fowler VG Jr. New molecular diagnostic approaches to bacterial infections and antibacterial resistance. Annu Rev Med. 2018;29(69):379\u201394.","journal-title":"Annu Rev Med"},{"key":"7018_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jac\/dkm497","volume":"61","author":"JJ Kerremans","year":"2008","unstructured":"Kerremans JJ, Verboom P, Stijnen T, et al. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother. 2008;61:428\u201335.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"7018_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1086\/421997","volume":"39","author":"L Simon","year":"2004","unstructured":"Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206\u201317.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7018_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12916-017-0795-7","volume":"15","author":"R Sager","year":"2017","unstructured":"Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017;15(1):15.","journal-title":"BMC Med"},{"issue":"12","key":"7018_CR50","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.cmi.2018.09.007","volume":"24","author":"Y van der Does","year":"2018","unstructured":"van der Does Y, Rood PPM, Ramakers C, et al. Identifying patients with bacterial infections using a combination of C-reactive protein, procalcitonin, TRAIL, and IP-10 in the emergency department: a prospective observational cohort study. Clin Microbiol Infect. 2018;24(12):1297\u2013304.","journal-title":"Clin Microbiol Infect"},{"key":"7018_CR51","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.biopha.2018.12.124","volume":"111","author":"MY Memar","year":"2019","unstructured":"Memar MY, Baghi HB. Presepsin: a promising biomarker for the detection of bacterial infections. Biomed Pharmacother. 2019;111:649\u201356.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"7018_CR52","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2174\/0929867325666180904120029","volume":"26","author":"G Larrouy-Maumus","year":"2019","unstructured":"Larrouy-Maumus G. Lipids as biomarkers of cancer and bacterial infections. Curr Med Chem. 2019;26(11):1924\u201332.","journal-title":"Curr Med Chem"},{"issue":"9","key":"7018_CR53","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/cid\/ciz540","volume":"70","author":"MM M\u00fccke","year":"2020","unstructured":"M\u00fccke MM, Mayer A, Kessel J, et al. Quinolone and multidrug resistance predicts failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2020;70(9):1916\u201324.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-07018-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-07018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T13:06:26Z","timestamp":1676120786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-07018-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7018"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-07018-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}